Exploiting the RNA interference pathway to counter hepatitis B virus replication
- PMID: 15698393
- DOI: 10.1111/j.1478-3231.2004.0966.x
Exploiting the RNA interference pathway to counter hepatitis B virus replication
Abstract
Chronic infection with hepatitis B virus (HBV) is endemic to sub-Saharan Africa and parts of Asia where persistence of the virus is commonly associated with complicating cirrhosis and hepatocellular carcinoma (HCC). Licensed therapies for HBV are partially effective in selected patients and development of novel treatments remains an important global medical objective. HBV has an unusually compact genome that restricts the ability of the virus to evade potentially therapeutic nucleic acid hybridization. Thus, exploiting the RNA interference (RNAi) pathway, which enables sequence-specific target RNA degradation using small interfering RNA (siRNA), is well suited to developing novel treatment for HBV infection. Several studies, both in vitro and in vivo, have demonstrated that HBV replication can be inhibited in transfected cells by synthetic siRNA duplexes and also Pol III-derived short hairpin RNA (shRNA) sequences. The effectiveness of anti-HBV sequences varies considerably, and is likely to result from differences in activation of the RNAi pathway by individual siRNA species. Exclusion of potentially toxic off-target effects and also development of efficient methods of hepatotropic nucleic acid delivery are important prerequisites before RNAi can be used successfully for anti-HBV treatment.
Similar articles
-
RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.Chin J Dig Dis. 2006;7(4):230-6. doi: 10.1111/j.1443-9573.2006.00268.x. Chin J Dig Dis. 2006. PMID: 17054586
-
Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.Int J Mol Med. 2007 Apr;19(4):705-11. Int J Mol Med. 2007. PMID: 17334648
-
The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.Antivir Ther. 2007;12(6):865-76. Antivir Ther. 2007. PMID: 17926641
-
Opportunities for treating chronic hepatitis B and C virus infection using RNA interference.J Viral Hepat. 2007 Jul;14(7):447-59. doi: 10.1111/j.1365-2893.2006.00818.x. J Viral Hepat. 2007. PMID: 17576386 Review.
-
Does RNA interference provide new hope for control of chronic hepatitis B infection?Antivir Ther. 2009;14(7):879-89. doi: 10.3851/IMP1424. Antivir Ther. 2009. PMID: 19918092 Review.
Cited by
-
The therapeutic potential of RNA interference.FEBS Lett. 2005 Oct 31;579(26):5996-6007. doi: 10.1016/j.febslet.2005.08.004. Epub 2005 Aug 15. FEBS Lett. 2005. PMID: 16115631 Free PMC article. Review.
-
Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics.Biochem J. 2007 Mar 1;402(2):251-60. doi: 10.1042/BJ20060961. Biochem J. 2007. PMID: 17064256 Free PMC article.
-
Progress and Prospects of Anti-HBV Gene Therapy Development.Int J Mol Sci. 2015 Jul 31;16(8):17589-610. doi: 10.3390/ijms160817589. Int J Mol Sci. 2015. PMID: 26263978 Free PMC article. Review.
-
RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells.PLoS One. 2012;7(3):e34060. doi: 10.1371/journal.pone.0034060. Epub 2012 Mar 23. PLoS One. 2012. PMID: 22457813 Free PMC article.
-
Silencing of hepatitis A virus infection by small interfering RNAs.J Virol. 2006 Jun;80(11):5599-610. doi: 10.1128/JVI.01773-05. J Virol. 2006. PMID: 16699041 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
